Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study
Diabetic macular edema is the most common cause of visual loss among patients with diabetic retinopathy. Pars plana vitrectomy has been reported to be effective for the treatment of diabetic macular edema. Previous report showed a limited improvement in visual acuity and macular thickness posterior intraoperative triamcinolone acetonide. Bevacizumab intravitreal injection has been proven be...
Brief Summary
Diabetic macular edema is the most common cause of visual loss among patients with diabetic retinopathy. Pars plana vitrectomy has been reported to be effective for the treatment of diabetic macular edema. Previous report showed a limited improvement in visual acuity and macular thickness posterior intraoperative triamcinolone acetonide. Bevacizumab intravitreal injection has been proven be effective in the treatment of diabetic macular edema, in recent publications. The purpose of this study is to evaluate whether vitrectomy with and without intravitreal triamcinolone acetonide and bevacizumab injection affects vision outcome and macular thickness in patients with diabetic macular edema.
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention(s) in this Clinical Trial
- Drug: Triamcinolone Acetonide and Bevacizumab
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Diffuse diabetic macular edema
- Non proliferative diabetic retinopathy
- No VPP previa
- No previous treament with laser, Triamcinolone acetonide, and Bevacizumab
Exclusion Criteria:
- Proliferative diabetic retinopathy
- Previous pars plana vitrectomy
- Previous treatment with diabetic macular edema
- Focal macular edema
- Macular Ischemia
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 20 Years
Maximum Age for this Clinical Trial: 90 Years
Clinical Trial Investigator Information
Lead Investigator: Asociación para Evitar la Ceguera en México Other
Overall Clinical Trial Officials and Contacts
Maximiliano Gordon, MD Principal Investigator APEC
Overall Contact: Maximiliano Gordon, MD 10841400 retinamex@yahoo.com
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00600301
Study ID Number: APEC-OO13
ClinicalTrials.gov Identifier: NCT00600301
Health Authority: Mexico: Secretaria de Salud
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00600301
